Literature DB >> 10993392

Hierarchical diagnosis in chronic schizophrenia: a clinical study of co-occurring syndromes.

P C Bermanzohn1, L Porto, P B Arlow, S Pollack, R Stronger, S G Siris.   

Abstract

Co-occurring or associated psychiatric syndromes (APS) such as depression, obsessive-compulsive disorder (OCD), and panic disorder have largely been hidden from view by exclusion rules that prohibit their being diagnosed in the presence of schizophrenia. This article presents data from a clinical study of APS in chronic schizophrenia and reviews the relevant literature. Thirty-seven chronic schizophrenia patients consecutively admitted to a day program were administered the Structured Clinical Interview for Diagnosis for DSM-IV and the Yale-Brown Obsessive Compulsive Scale symptom checklist. Exclusion rules prohibiting the diagnosis of APS were bypassed. Eighteen patients (48.6%) had one or more APS. Ten patients (27%) had major depression. Eleven (29.7%) met criteria for OCD. Four patients (10.8%) met criteria for panic disorder. These findings suggest that APS may be common in chronic schizophrenia and that there is a need to study these syndromes' clinical validity, including their treatability. A research plan to study the validity of these syndromes further is discussed.

Entities:  

Mesh:

Year:  2000        PMID: 10993392     DOI: 10.1093/oxfordjournals.schbul.a033472

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  22 in total

1.  Association of stigma, self-esteem, and symptoms with concurrent and prospective assessment of social anxiety in schizophrenia.

Authors:  Paul H Lysaker; Philip T Yanos; Jared Outcalt; David Roe
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-04

2.  Evaluation of Myo-Inositol as a Potential Biomarker for Depression in Schizophrenia.

Authors:  Joshua Chiappelli; Laura M Rowland; S Andrea Wijtenburg; Florian Muellerklein; Malle Tagamets; Robert P McMahon; Frank Gaston; Peter Kochunov; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2015-02-27       Impact factor: 7.853

Review 3.  The complement system in schizophrenia.

Authors:  Karine R Mayilyan; Daniel R Weinberger; Robert B Sim
Journal:  Drug News Perspect       Date:  2008-05

4.  The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis.

Authors:  Stephan F Taylor; Tyler B Grove; Vicki L Ellingrod; Ivy F Tso
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

5.  Interventions for obsessive compulsive symptoms in people with schizophrenia.

Authors:  Mohan Raj; Saeed Farooq
Journal:  Cochrane Database Syst Rev       Date:  2005

6.  Prevalence of Substance Use in Patients Diagnosed with Schizophrenia.

Authors:  Yasemin Tekin Uludağ; Gülcan Güleç
Journal:  Noro Psikiyatr Ars       Date:  2016-03-01       Impact factor: 1.339

7.  The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders.

Authors:  Lieuwe de Haan; Bouke Sterk; Luuk Wouters; Don H Linszen
Journal:  Schizophr Bull       Date:  2011-07-28       Impact factor: 9.306

Review 8.  How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association.

Authors:  Amélie M Achim; Michel Maziade; Eric Raymond; David Olivier; Chantal Mérette; Marc-André Roy
Journal:  Schizophr Bull       Date:  2009-12-03       Impact factor: 9.306

9.  Comparative Analysis of Cognitive Function in Schizophrenia with and without Obsessive Compulsive Disorder.

Authors:  Myung-Ji Lee; Yong-Bum Shin; Young-Kyung Sunwoo; Seung-Ho Jung; Won-Hyoung Kim; Min-Hee Kang; Jeong-Seop Lee; Jae-Nam Bae; Chul-Eung Kim
Journal:  Psychiatry Investig       Date:  2009-11-09       Impact factor: 2.505

Review 10.  Psychiatric comorbidities and schizophrenia.

Authors:  Peter F Buckley; Brian J Miller; Douglas S Lehrer; David J Castle
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.